Are you ready to dive into the groundbreaking advancements that reshaped kidney care in November 2025? Buckle up, because it was a month packed with pivotal trial results, key FDA approvals, and fresh insights into transplantation and chronic kidney disease (CKD). So much happened, you might have missed something crucial!
November 2025 was a whirlwind of activity in the world of nephrology. From the buzz surrounding the American Society of Nephrology (ASN) Kidney Week 2025 to significant strides in managing IgA nephropathy (IgAN), crucial approvals from the US Food and Drug Administration (FDA), and the release of late-stage trial results, HCPLive was on the front lines, capturing the most important developments impacting kidney health.
This month's highlights demonstrate just how rapidly kidney therapies and clinical management are evolving. Let's focus on IgAN for a moment. Emerging therapies that specifically target the immune system, including sibeprenlimab, telitacicept, and atacicept, are showing impressive results. We're seeing meaningful reductions in proteinuria (protein in the urine – a key indicator of kidney damage), improvements in pathogenic biomarkers (substances in the body that signal disease), and, most excitingly, signs that these therapies could actually modify the disease's progression in patients at risk. Think of it like this: we're not just treating the symptoms; we're potentially slowing down or even halting the disease itself!
And this is the part most people miss... The advances don't stop there. In focal segmental glomerulosclerosis (FSGS) and membranous nephropathy, agents like sparsentan and MIL62 are demonstrating the potential to increase remission rates and improve long-term kidney outcomes. Now imagine a world where more patients achieve remission and maintain healthier kidneys for longer. That's the future these advancements are pointing towards.
Progress in kidney transplantation and immunosuppression is also offering valuable insights. For example, safer rejection prevention using tegoprubart and supportive data on post-transplant pregnancies are providing actionable information for clinicians managing complex cases. It's not just about keeping the new kidney functioning; it's about ensuring the overall health and well-being of the patient, including their ability to start or expand their families.
Developments across chronic kidney disease (CKD), dialysis, and even rare kidney disorders are further expanding the therapeutic landscape. New FDA orphan drug designations and late-stage trial readouts are providing hope for patients with conditions that previously had limited treatment options. This is about expanding the toolkit available to healthcare professionals so that they can provide the best possible, evidence-based care.
Ready for a deeper dive? Here's a recap of HCPLive's coverage of the top renal news and research from November 2025:
1. FDA Awards Accelerated Approval to Sibeprenlimab in IgA Nephropathy:
The FDA granted accelerated approval to sibeprenlimab (Voyxact), a targeted APRIL inhibitor, for adults with IgAN who are at risk of their disease getting worse. The phase 3 VISIONARY trial showed promising safety results, a significant 54.3% reduction in proteinuria, a decrease in galactose-deficient immunoglobulin A1 (Gd-IgA1) (a specific type of antibody linked to IgAN), and improvements in other disease biomarkers. This approval provides a new treatment option for patients whose kidneys are at risk of failing due to IgAN.
2. Telitacicept Achieves Primary Endpoint in IgA Nephropathy Phase 3 Study:
Telitacicept, a biologic drug that modulates B-cells (a type of immune cell), met its primary endpoint in a phase 3 study. Researchers reported a -58.9% change in the amount of protein in the urine over a 24-hour period (measured as the 24h-UPCR) compared to only -8.8% for the placebo group (P <.0001). The drug also had a favorable safety profile. These findings suggest that telitacicept could be a disease-modifying therapy for IgAN patients at high risk of kidney failure.
3. Understanding Atacicept & 36-Week ORIGIN 3 Data from Kidney Week 2025, With Jonathan Barratt, MBChB, PhD:
Interim results from the ORIGIN-3 trial, presented at ASN Kidney Week 2025, showed that atacicept (a dual BAFF/APRIL inhibitor) led to a 68.3% decrease in Gd-IgA1, resolution of blood in the urine (dipstick hematuria) in 81.0% of patients, and a 47.3% reduction in the urinary albumin-to-creatinine ratio (another measure of protein in the urine). Jonathan Barratt, MBChB, PhD, discusses atacicept’s potential role in treating IgAN.
4. PROTECT: Sparsentan Offers CV Protection Benefits as First-Line Therapy in IgAN:
A 24-week analysis from the SPARTAN study suggests that sparsentan (Filspari), a dual endothelin and angiotensin receptor antagonist, leads to rapid reductions in proteinuria (around 70%) along with improvements in blood pressure, heart structure, and cardiovascular biomarkers. This supports the idea that sparsentan could be used as a first-line therapy for adults with IgAN.
5. DUPLEX: Sparsentan Outperforms Irbesartan in Key Proteinuria Threshold in FSGS:
The phase 3 DUPLEX trial showed that sparsentan achieved earlier and more frequent reductions in proteinuria (UPCR <0.7 g/g) and improved long-term kidney outcomes compared with irbesartan in patients with focal segmental glomerulosclerosis (FSGS). Essentially, sparsentan helped patients get to a healthier level of protein in their urine faster and kept their kidneys healthier for longer compared to irbesartan, a standard treatment.
6. MIL62 Shows Increased Remission and Reduced Relapse Versus Cyclosporine A in MN:
In adults with primary membranous nephropathy (MN), MIL62 achieved complete remission in 49.4% of patients by week 76, compared to only 3.9% with cyclosporine A. Overall remission rates were consistently higher at weeks 24, 52, and 76 (all P <.001), indicating that MIL62 provides more durable disease control than cyclosporine A, a commonly used immunosuppressant.
7. BESTOW: Tegoprubart Showcases Safer Prevention of Kidney Transplant Rejection Over Tacrolimus:
Phase 2 BESTOW trial data suggest that tegoprubart offers similar improvements in estimated glomerular filtration rate (eGFR) as tacrolimus, but with a better safety profile. This could potentially change the way doctors prevent kidney transplant rejection, making it safer for patients.
8. Global Data Support Successful Pregnancy Outcomes in Kidney Transplant Recipients:
Analyses of data from registries across multiple continents show that pregnancy after kidney transplantation can be successfully managed, with good outcomes for the mother, the baby, and the transplanted kidney. These findings emphasize the importance of careful monitoring and the need for international collaboration to improve outcomes in high-risk pregnancies.
9. FDA Grants Orphan Drug Designation to ABBV-CLS-628 for ADPKD:
The FDA granted orphan drug designation to ABBV-CLS-628 for autosomal dominant polycystic kidney disease (ADPKD). This designation, given to drugs for rare diseases, provides incentives for further development and research into this potential new treatment option.
The field of nephrology is clearly on the move! What do you think about the rapid pace of innovation in kidney care? Are these new therapies truly game-changers, or do we need more long-term data before we can celebrate? And considering the high cost of many of these treatments, how can we ensure that all patients have access to the care they need? Share your thoughts in the comments below!
)
